A detailed history of Royal Bank Of Canada transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 2,509 shares of KROS stock, worth $114,661. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,509
Previous 8,927 71.89%
Holding current value
$114,661
Previous $354,000 53.11%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$41.26 - $70.48 $264,806 - $452,340
-6,418 Reduced 71.89%
2,509 $166,000
Q4 2023

Feb 14, 2024

BUY
$27.12 - $41.05 $103,164 - $156,154
3,804 Added 74.25%
8,927 $354,000
Q3 2023

Nov 14, 2023

SELL
$31.57 - $43.02 $378 - $516
-12 Reduced 0.23%
5,123 $163,000
Q2 2023

Aug 14, 2023

BUY
$37.26 - $51.01 $102,204 - $139,920
2,743 Added 114.67%
5,135 $206,000
Q1 2023

May 15, 2023

SELL
$41.44 - $59.32 $23,745 - $33,990
-573 Reduced 19.33%
2,392 $102,000
Q4 2022

Feb 14, 2023

BUY
$39.45 - $51.77 $98,072 - $128,700
2,486 Added 519.0%
2,965 $142,000
Q3 2022

Nov 14, 2022

BUY
$27.8 - $40.12 $3,419 - $4,934
123 Added 34.55%
479 $18,000
Q2 2022

Aug 15, 2022

SELL
$26.03 - $67.04 $22,880 - $58,928
-879 Reduced 71.17%
356 $10,000
Q1 2022

May 16, 2022

SELL
$42.12 - $59.36 $102,814 - $144,897
-2,441 Reduced 66.4%
1,235 $67,000
Q4 2021

Feb 14, 2022

BUY
$36.95 - $62.89 $82,878 - $141,062
2,243 Added 156.52%
3,676 $215,000
Q3 2021

Nov 15, 2021

BUY
$29.27 - $43.71 $7,727 - $11,539
264 Added 22.58%
1,433 $57,000
Q2 2021

Aug 16, 2021

BUY
$42.4 - $70.11 $49,565 - $81,958
1,169 New
1,169 $49,000

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.18B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.